Aquestive Therapeutics (AQST) vs Climb Bio (CLYM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Climb Bio (CLYM) has outperformed Aquestive Therapeutics (AQST) over the past year, gaining 503.3% versus a loss of 23.2%. Over five years, AQST leads with a +23.0% price change compared with -32.7% for CLYM. Climb Bio is the larger company by market cap ($623.8 million vs $597.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AQST | CLYM |
|---|---|---|
| Share price | $4.76 | $10.86 |
| Market cap | $597.44M | $623.76M |
| 1-day change | +3.03% | +1.40% |
| YTD return | -26.32% | +171.50% |
| 1-year return | -23.23% | +503.33% |
| 5-year return | +23.00% | -32.71% |
| EPS (TTM) | $-0.66 | $-0.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.55 | $18.33 |
| 52-week low | $2.93 | $1.64 |
| Distance from 52-week high | -36.95% | -40.75% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +96.01% | +153.87% |
| Average volume | 2.68M | 1.37M |
| Shares outstanding | 125.51M | 57.44M |
| Employees | 147 | 28 |
| Sector | Healthcare | Health Care |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLYM has outperformed AQST by 526.6 percentage points over the past year.
- The two companies sit in different sectors: Aquestive Therapeutics in Healthcare and Climb Bio in Health Care.
About Aquestive Therapeutics
AQST stock →Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Healthcare · Drug Manufacturers - Specialty & Generic · 147 employees
About Climb Bio
CLYM stock →Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
AQST vs CLYM FAQ
Which is bigger, Aquestive Therapeutics or Climb Bio?
Climb Bio (CLYM) is larger, with a market capitalization of $623.76M compared with $597.44M for Aquestive Therapeutics (AQST).
Which stock has performed better over the past year, AQST or CLYM?
CLYM returned +503.33% over the past 12 months, compared with -23.23% for AQST (price return, excluding dividends). Past performance does not predict future results.
Are Aquestive Therapeutics and Climb Bio in the same industry?
No. Aquestive Therapeutics is in the Healthcare sector, while Climb Bio is in Health Care.